EPM2A
Reactivity: Human
WB, ELISA
Host: Mouse
Polyclonal
unconjugated
Application Notes
ELISA. Western blot (1: 1,000 - 1: 2,000). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
1.0 mg/mL
Buffer
PBS, pH 7.4, containing 0.09 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for up to two weeks or (in aliquots) at -20 °C forlonger. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
Expiry Date
12 months
Target
EPM2A
(Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy.Synonyms: EC=3.1.3.16, EC=3.1.3.48, EPM2A, LAFPTPase, Lafora PTPase, Laforin